JP2023524169A - 医薬化合物の結晶形態 - Google Patents
医薬化合物の結晶形態 Download PDFInfo
- Publication number
- JP2023524169A JP2023524169A JP2022577645A JP2022577645A JP2023524169A JP 2023524169 A JP2023524169 A JP 2023524169A JP 2022577645 A JP2022577645 A JP 2022577645A JP 2022577645 A JP2022577645 A JP 2022577645A JP 2023524169 A JP2023524169 A JP 2023524169A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- crystalline form
- crystalline
- disease
- reflections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024015037A JP2024054192A (ja) | 2020-10-02 | 2024-02-02 | 医薬化合物の結晶形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20199934.9 | 2020-10-02 | ||
| EP20199934.9A EP3978474A1 (en) | 2020-10-02 | 2020-10-02 | Crystalline forms of a pharmaceutical compound |
| PCT/EP2021/077100 WO2022069709A1 (en) | 2020-10-02 | 2021-10-01 | Crystalline forms of a pharmaceutical compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024015037A Division JP2024054192A (ja) | 2020-10-02 | 2024-02-02 | 医薬化合物の結晶形態 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2023524169A true JP2023524169A (ja) | 2023-06-08 |
Family
ID=72744696
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577645A Pending JP2023524169A (ja) | 2020-10-02 | 2021-10-01 | 医薬化合物の結晶形態 |
| JP2024015037A Pending JP2024054192A (ja) | 2020-10-02 | 2024-02-02 | 医薬化合物の結晶形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024015037A Pending JP2024054192A (ja) | 2020-10-02 | 2024-02-02 | 医薬化合物の結晶形態 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12116344B2 (enExample) |
| EP (3) | EP3978474A1 (enExample) |
| JP (2) | JP2023524169A (enExample) |
| KR (2) | KR102659466B1 (enExample) |
| CN (1) | CN116390910A (enExample) |
| AU (2) | AU2021353055B2 (enExample) |
| BR (2) | BR112022018020B1 (enExample) |
| CA (1) | CA3193939C (enExample) |
| CL (1) | CL2023000943A1 (enExample) |
| DK (1) | DK4114826T3 (enExample) |
| ES (1) | ES2964105T3 (enExample) |
| FI (1) | FI4114826T3 (enExample) |
| IL (2) | IL301882B2 (enExample) |
| MA (1) | MA58885B1 (enExample) |
| MX (1) | MX2023003618A (enExample) |
| PE (1) | PE20240138A1 (enExample) |
| TW (1) | TW202229236A (enExample) |
| WO (1) | WO2022069709A1 (enExample) |
| ZA (1) | ZA202310184B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202337456A (zh) * | 2022-01-10 | 2023-10-01 | 荷蘭商雅捷法羅斯公司 | Ｇｍ２神經節苷脂症之治療 |
| EP4209215A1 (en) * | 2022-01-10 | 2023-07-12 | Azafaros B.V. | Treatment of gm2 gangliosidosis |
| WO2025162745A1 (en) | 2024-02-01 | 2025-08-07 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
| EP4595964A1 (en) | 2024-02-01 | 2025-08-06 | Azafaros B.V. | Treatment of gm1 gangliosidosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015147639A1 (en) * | 2014-03-27 | 2015-10-01 | Academisch Medisch Centrum | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
| JP2018527946A (ja) * | 2015-06-24 | 2018-09-27 | ウニフェルシタイト・ライデン | グリコシル化代謝産物 |
-
2020
- 2020-10-02 EP EP20199934.9A patent/EP3978474A1/en not_active Withdrawn
-
2021
- 2021-10-01 PE PE2023001212A patent/PE20240138A1/es unknown
- 2021-10-01 CN CN202180067242.0A patent/CN116390910A/zh active Pending
- 2021-10-01 WO PCT/EP2021/077100 patent/WO2022069709A1/en not_active Ceased
- 2021-10-01 KR KR1020237014953A patent/KR102659466B1/ko active Active
- 2021-10-01 BR BR112022018020-9A patent/BR112022018020B1/pt active IP Right Grant
- 2021-10-01 MA MA58885A patent/MA58885B1/fr unknown
- 2021-10-01 DK DK21798287.5T patent/DK4114826T3/da active
- 2021-10-01 BR BR122022018214-3A patent/BR122022018214A2/pt not_active Application Discontinuation
- 2021-10-01 MX MX2023003618A patent/MX2023003618A/es unknown
- 2021-10-01 US US18/029,842 patent/US12116344B2/en active Active
- 2021-10-01 EP EP23191550.5A patent/EP4295847A3/en active Pending
- 2021-10-01 ES ES21798287T patent/ES2964105T3/es active Active
- 2021-10-01 EP EP21798287.5A patent/EP4114826B1/en active Active
- 2021-10-01 KR KR1020247012671A patent/KR20240056628A/ko active Pending
- 2021-10-01 IL IL301882A patent/IL301882B2/en unknown
- 2021-10-01 AU AU2021353055A patent/AU2021353055B2/en active Active
- 2021-10-01 FI FIEP21798287.5T patent/FI4114826T3/fi active
- 2021-10-01 IL IL316634A patent/IL316634A/en unknown
- 2021-10-01 CA CA3193939A patent/CA3193939C/en active Active
- 2021-10-01 JP JP2022577645A patent/JP2023524169A/ja active Pending
- 2021-10-01 TW TW110136766A patent/TW202229236A/zh unknown
-
2022
- 2022-12-20 AU AU2022291486A patent/AU2022291486B2/en active Active
-
2023
- 2023-03-30 CL CL2023000943A patent/CL2023000943A1/es unknown
- 2023-10-30 ZA ZA2023/10184A patent/ZA202310184B/en unknown
-
2024
- 2024-02-02 JP JP2024015037A patent/JP2024054192A/ja active Pending
- 2024-08-30 US US18/821,921 patent/US20250059137A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015147639A1 (en) * | 2014-03-27 | 2015-10-01 | Academisch Medisch Centrum | N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase |
| JP2018527946A (ja) * | 2015-06-24 | 2018-09-27 | ウニフェルシタイト・ライデン | グリコシル化代謝産物 |
Non-Patent Citations (6)
| Title |
|---|
| GHISAIDOOBE, A. T. ET AL.: "Identification and Development of Biphenyl Substituted Iminosugars as Improved Dual Glucosylceramide", J. MED. CHEM., vol. 57, JPN6023023851, 2014, pages 9096 - 9104, ISSN: 0005291965 * |
| LAHAV, D. ET AL.: "A Fluorescence Polarization Activity-Based Protein Profiling Assay in the Discovery of Potent, Selec", J. AM. CHEM. SOC., vol. 139, JPN6023023849, 2017, pages 14192 - 14197, ISSN: 0005291964 * |
| 浅原 照三, 溶剤ハンドブック, JPN6011026738, 1985, pages 47 - 51, ISSN: 0005291966 * |
| 社団法人日本化学会編, 第４版 実験化学講座１ 基本操作Ｉ, vol. 第２刷, JPN6016031896, 5 April 1996 (1996-04-05), pages 184 - 186, ISSN: 0005291968 * |
| 第十七改正日本薬局方, JPN6023012544, 7 March 2016 (2016-03-07), pages 71 - 74, ISSN: 0005291969 * |
| 高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005291967 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022291486B2 (en) | Crystalline forms of a pharmaceutical compound | |
| EA019819B1 (ru) | Кристаллическая полиморфная форма с ингибитора белка, активирующего 5-липоксигеназу, фармацевтическая композиция на ее основе и применение в лечении | |
| US20250120958A1 (en) | Treatment of GM2 Gangliosidosis | |
| US7964604B2 (en) | Bifeprunox mesylate maintenance dose compositions and methods for using the same | |
| EP3505515B1 (en) | Crystals of cyclic amine derivative and pharmaceutical use thereof | |
| NZ798892B2 (en) | Crystalline forms of a pharmaceutical compound | |
| EA045552B1 (ru) | Кристаллические формы фармацевтического соединения | |
| HK40087007B (en) | Crystalline forms of a pharmaceutical compound | |
| HK40087007A (en) | Crystalline forms of a pharmaceutical compound | |
| CN118632693A (zh) | Gm2神经节苷脂贮积症的治疗 | |
| WO2025219951A1 (en) | Venglustat for use in methods for reducing disease related biomarker levels in patients with ganglioside storage disorders | |
| WO2024263878A2 (en) | Solid forms of posiphen d-tartrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20221215 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221215 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20221216 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230613 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230904 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240207 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240228 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240329 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251118 |